The antibody treatment that President Trump was given after his coronavirus diagnosis will likely not be widely available to the country, according to the CEO of the company that manufactured the medical concoction.
Regeneron CEO Leonard Schleifer told CBS News’s “Face the Nation” on Sunday that there are not enough doses of its product to be distributed widely among the public.
Schleifer told hold Margaret Brennan that the distribution details will be worked out by the government, the Food and Drug Administration and the ethical experts to give the products to those most in need, such as the elderly and those in high-risk categories.
“We have to figure out ways to ration this,” he said.
President Trump inaccurately called the treatment a cure last week and said he wanted to make accessible to patients at no cost. He added that he had emergency use authorization “all set.”
The president made the announcement shortly before the company actually applied for the emergency use authorization.
Trump is on the short list of people who have used the experimental drug derived from fetal tissue.
The real impact of a drug comes from how it can perform on average in large clinical trials that are ongoing, Schleifer said.
“We’ve got some preliminary evidence that we’ve talked with the FDA, and we’re going for an emergency use authorization, because we think it’s appropriate at this time,” he said. “But yes, the president’s case is a case report, perhaps the most analyzed case report ever.”